A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.
- Status
- planned
- Phase
- Phase 2, Phase 3
- Institution
- COMPASS Pathways
- Start date
- 2026-09-01
- End date
- 2029-09-01
- Registry ID
- NCT07570654
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.